Étienne Chatelut (Etienne Chatelut)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 21

Top Topics

Neuroendocrine Tumors

Chronic Lymphocytic Leukemia

Clinical Practice

Top Venues

Clinical pharmacokinetics

British journal of clinical pharmacology

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Florent Puisset, Mourad Mseddi, Loïc Mourey, Damien Pouessel, Benoit Blanchet, Étienne Chatelut, Christine Chevreau
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer. Cancers 15 (1) (2023)
Florent Puisset, Mourad Mseddi, Loïc Mourey, Damien Pouessel, Benoit Blanchet, Étienne Chatelut, Christine Chevreau
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer. Cancers 15 (1) (2023)
Félicien Le Louedec, Florent Puisset, Étienne Chatelut, Michel Tod
Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice. Clinical pharmacokinetics 62 (1) (2023)
Marie Lambert, Mathieu Alonso, Caroline Munzer, Marie-Christine Zimoch, Laurence Malard, Marion Gambart, Marie-Pierre Castex, Carla Martins, Marlène Pasquet, Étienne Chatelut
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer. Cancer chemotherapy and pharmacology (2023)
Félicien Le Louedec, Florent Puisset, Étienne Chatelut, Michel Tod
Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice. Clinical pharmacokinetics 62 (1) (2023)
Florent Puisset, Félicien Le Louedec, Florence Dalenc, Lorène Verguet, Eleonora De Maio, Jean Louis Lacaze, Marion Montastruc, Mony Ung, Camille Vinson, Sophie Perriat, Sandrine Pacher, Étienne Chatelut, Mélanie White Koning
Investigating the clinical impact of dose-banding for weekly paclitaxel in patients with breast cancer: a retrospective and monocentric study. British journal of clinical pharmacology (2023)
Félicien Le Louedec, Florent Puisset, Étienne Chatelut, Michel Tod
Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice. Clinical pharmacokinetics 62 (1) (2023)
Félicien Le Louedec, Florent Puisset, Étienne Chatelut, Michel Tod
Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice. Clinical pharmacokinetics (2023)
Florent Puisset, Félicien Le Louedec, Florence Dalenc, Lorène Verguet, Eleonora De Maio, Jean Louis Lacaze, Marion Montastruc, Mony Ung, Camille Vinson, Sophie Perriat, Sandrine Pacher, Étienne Chatelut, Mélanie White Koning
Investigating the clinical impact of dose-banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study. British journal of clinical pharmacology (2023)
Florent Puisset, Mourad Mseddi, Loïc Mourey, Damien Pouessel, Benoit Blanchet, Étienne Chatelut, Christine Chevreau
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer. Cancers 15 (1) (2023)
Félicien Le Louedec, Florent Puisset, Étienne Chatelut, Michel Tod
Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice. Clinical pharmacokinetics 62 (1) (2023)
Étienne Chatelut, Félicien Le Louedec, Gérard Milano
Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology. Clinical pharmacokinetics 59 (3) (2021)
Félicien Le Louedec, Florent Puisset, Fabienne Thomas, Étienne Chatelut, Melanie White-Koning
Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr. CPT: pharmacometrics & systems pharmacology 10 (10) (2021)
Étienne Chatelut, Jeroen J M A Hendrikx, Jennifer H Martin, Joseph Ciccolini, Dirk Jan A R Moes
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacology research & perspectives 9 (2) (2021)
Félicien Le Louedec, Étienne Chatelut
Correlation Between Bevacizumab Exposure and Survival Does Not Necessarily Imply Causality. The oncologist 25 (12) (2020)
Sotheara Moeung, Christine Chevreau, Sabrina Marsili, Christophe Massart, Aude Fléchon, Rémy Delva, Gwenaëlle Gravis, Jean-Pierre Lotz, Jacques-Olivier Bay, Marine Gross-Goupil, Thomas Filleron, Caroline Delmas, Thierry Lafont, Étienne Chatelut, Fabienne Thomas
Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors. Pharmaceutical research 37 (7) (2020)
Maud Maillard, Félicien Le Louedec, Fabienne Thomas, Étienne Chatelut
Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review. Expert opinion on drug metabolism & toxicology 16 (10) (2020)
Alicja Puszkiel, Mathilde Bauriaud-Mallet, Roxane Bourgeois, Lawrence Dierickx, Frédéric Courbon, Étienne Chatelut
Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Clinical pharmacokinetics 58 (2) (2020)
Marie Lambert, Melanie White-Koning, Mathieu Alonso, Arnaud Garnier, Gwennaelle Alphonsa, Chloé Puiseux, Caroline Munzer, Joseph Berthier, Laurence Malard, Marlène Pasquet, Étienne Chatelut
Plasma cystatin C is a marker of renal glomerular injury in children treated with cisplatin or ifosfamide. Pediatric blood & cancer 68 (1) (2020)
Chloé Medrano, Lucie Oberic, Florent Puisset, Christian Recher, Delphine Larrieu-Ciron, Loïc Ysebaert, Caroline Protin, Muriel Picard, Sophie Perriat, Étienne Chatelut, Sarah Bertoli, Françoise Huguet, Suzanne Tavitian, Stanislas Faguer
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients. Leukemia & lymphoma 62 (4) (2020)
Fabienne Thomas, Gareth J Veal, Souleiman El Balkhi, Thierry Lafont, Nicolas Picard, Laurence Brugieres, Étienne Chatelut, Christophe Piguet
Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer chemotherapy and pharmacology 82 (2) (2018)